Fit-for-Purpose Rapid Gradient HILIC-MS Analysis for N-Glycan Profiling

Significance of the Topic

Released N‑glycan profiling of monoclonal antibodies is a central analytical approach for defining critical quality attributes (CQAs) that influence therapeutic efficacy, safety, and pharmacokinetics. Rapid, robust assays that quantify glycan maturity (e.g., G0/G1/G2 distribution), core fucosylation and high‑mannose content are increasingly required to support high‑throughput clone selection, process development, near‑real‑time bioprocess monitoring and routine QC release. Shortening chromatographic run times while preserving quantitative fidelity addresses a major throughput bottleneck in contemporary biomanufacturing analytics.

Objectives and Study Overview

This application note evaluates a shortened 10‑minute HILIC gradient for released N‑glycan analysis and compares its performance to a conventional 55‑minute HILIC method. The goal was to determine whether the accelerated method provides quantitatively equivalent glycan profiles for major and clinically relevant species, and whether it can reliably detect biologically induced glycosylation changes in CHO cell culture samples subjected to targeted supplementation (2‑F‑peracetyl‑fucose and galactose).

Methodology

• Biological system: NISTCHO cells producing a reference IgG1 (NISTmAb) grown in fed‑batch shake‑flask cultures with controlled glucose and feed strategies; supplements (2‑F‑peracetyl‑fucose or galactose) were added to modulate glycosylation.
• Sample processing: Automated Protein A capture and an automated glycan release and labeling workflow using PNGase F and the GlycoWorks RapiFluor‑MS labeling chemistry implemented on an Andrew+ liquid handling robot; SPE cleanup on µElution plates prior to analysis.
• Chromatography: Hydrophilic interaction liquid chromatography (HILIC) comparing a conventional 55‑minute gradient on a 150 mm column to an accelerated 10‑minute gradient on a 50 mm column.
• Detection and data handling: Mass‑selective detection (high‑resolution MS) combined with extracted ion chromatograms (XICs) for glycan class isolation and quantitation; triplicate injections for precision assessment.
• Performance metrics: Relative abundances of major glycan species (G0/G1/G2, G0F/G1F/G2F, high‑mannose), %fucosylation and %galactosylation; comparison across control and supplemented cultures.

Instrumentation Used

• BioAccord Premier high‑resolution LC–MS system (Waters)
• ACQUITY Premier UPLC platform (Waters)
• Andrew+ automated liquid handling robot for Protein A purification and automated glycan release/labeling
• GlycoWorks RapiFluor‑MS N‑Glycan labeling kit and related SPE consumables
• Protein A affinity resin for antibody capture; µElution SPE plates for cleanup
• BioProfile FLEX2 analyzer for routine metabolite monitoring

Main Results and Discussion

• The 10‑minute HILIC method produced glycan profiles for major Fc species that were quantitatively equivalent to the 55‑minute method. Summed glycan class abundances (e.g., total G1F as the sum of positional isomers) were preserved within analytical variability.
• Chromatographic tradeoffs: The accelerated method showed reduced resolution for certain isomeric pairs (notably G1F positional isomers), resulting in partial co‑elution. However, mass‑selective detection and reporting of summed glycan classes mitigated this limitation for routine CQA reporting.
• Biological sensitivity: The 10‑minute workflow accurately captured mechanistic glycosylation changes induced by supplements: 2‑F‑peracetyl‑fucose caused marked reductions in core‑fucosylated species with reciprocal increases in afucosylated counterparts, while galactose feeding shifted distributions toward higher mono‑ and di‑galactosylated species. Both effects were concordant between the 10‑ and 55‑minute methods.
• Precision and limits: Major glycan species showed low variability between methods and replicates. Low‑abundance glycans near the LOQ exhibited higher %RSDs, reflecting sensitivity limits rather than systematic bias from the shortened gradient.
• Regulatory context: Because routine comparability and maturity reporting typically rely on summed glycan categories rather than isomer‑level resolution, the 10‑minute method aligns with regulatory expectations for reproducible quantitation of anticipated glycoforms.

Benefits and Practical Applications

• Throughput: Run time reduced by ~80% (10 min vs 55 min), enabling substantially higher sample throughput and potential near‑real‑time glycosylation surveillance in process development and manufacturing support.
• Fit‑for‑purpose reporting: Preserves quantitative fidelity for clinically relevant attributes—%galactosylation, %fucosylation, and high‑mannose—that inform product quality, functional performance and lot comparability.
• Workflow integration: Compatible with automated sample prep and data workflows, facilitating large‑scale clone screening, media/feed optimization studies, and routine QC assays.
• Resource efficiency: Shorter runs reduce instrument occupancy, solvent use and per‑sample time-to‑result, benefiting operational efficiency in high‑throughput environments.

Future Trends and Potential Applications

• Further automation and inline sample preparation to approach true near‑real‑time analytics for bioprocess control and adaptive manufacturing.
• Enhanced MS‑based deconvolution and data‑processing tools to better handle co‑eluting isomers and to extend confident quantitation of low‑abundance species in short gradients.
• Application of accelerated HILIC workflows to broader product classes (e.g., Fc‑fusion proteins, glycoengineered modalities) and to multiplexed screening campaigns.
• Integration with PAT (process analytical technology) frameworks and model‑based process control using high‑frequency glycan data to inform critical process parameter adjustments.

Conclusion

The evaluated 10‑minute HILIC‑MS method delivers a pragmatic balance between speed and quantitative accuracy for released N‑glycan profiling of IgG Fc glycans. While reduced chromatographic resolution affects isomer separation, mass‑selective detection and reporting of summed glycan classes preserve the clinical and regulatory information required for CQA assessment. The method is fit‑for‑purpose for high‑throughput process development and routine QC where rapid, reproducible monitoring of %fucosylation, %galactosylation and high‑mannose content is needed.

References

1. Crescioli S.; et al. Antibodies to Watch in 2024. mAbs 2024, 16(1), 2297450.
2. Ecker D. M.; Jones S. D.; Levine H. L. The Therapeutic Monoclonal Antibody Market. mAbs 2015, 7(1), 9–14.
3. Reusch D.; Tejada M. Fc Glycans of Therapeutic Antibodies as Critical Quality Attributes. Glycobiology 2015, 25, 1325–1334.
4. Mimura Y.; et al. Glycosylation Engineering of Therapeutic IgG Antibodies: Challenges for the Safety, Functionality and Efficacy. Protein Cell 2018, 9, 47–62.
5. Shinkawa T.; et al. The absence of fucose but not the presence of galactose or bisecting N‑acetylglucosamine of human IgG1 complex‑type oligosaccharides shows the critical role of enhancing antibody‑dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466–3473.
6. Shields R. L.; et al. Lack of fucose on human IgG1 N‑linked oligosaccharide improves binding to human Fc gamma RIII and antibody‑dependent cellular toxicity. J. Biol. Chem. 2002, 277, 26733–26740.
7. Goetze A. M.; et al. High‑mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011, 21(7), 949–959.
8. Houel S.; et al. N‑ and O‑Glycosylation Analysis of Etanercept Using LC and Q‑TOF MS with ETD Functionality. Anal. Chem. 2014, 86, 576–584.
9. Lauber M. A.; et al. Rapid Preparation of Released N‑Glycans for HILIC Analysis Using a Labeling Reagent that Facilitates Sensitive Fluorescence and ESI‑MS Detection. Anal. Chem. 2015, 87(10), 5401–5409.
10. Segu Z.; et al. A rapid method for relative quantification of N‑glycans from a therapeutic monoclonal antibody during trastuzumab biosimilar development. mAbs 2020, 12(1), 1750794.
11. Dahodwala H.; et al. Development and Characterization of the NISTCHO Reference Cell Line. Biotechnol. J. 2025, 20(5), e70012.
12. Alelyunas Y. W.; Wushensky J.; Wrona M.; Chen R. Analytical Scale 96‑well Protein A Affinity Resin‑Based Purification using Andrew+ Automation Robot Supporting Upstream Bioprocessing. Waters Application Note 2025.
13. GlycoWorks RapiFluor‑MS N‑Glycan Care and Use Manual. Waters 2024.
14. ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999 (adopted by FDA).
15. Becker D. J.; Lowe J. B. Fucose: Biosynthesis and Biological Function in Mammals. Glycobiology 2003, 13(7), 41R–53R.
16. Wells E. J.; et al. Media Supplementation with 2‑F‑Peracetyl‑Fucose and Galactose Differentially Modulates Antibody Glycosylation in CHO Cells. Biotechnol. Bioeng. 2020, 117(11), 3310–3321.
17. Ehret J.; et al. Impact of Cell Culture Media Additives on IgG Glycosylation Produced in CHO Cells. Biotechnol. Bioeng. 2018, 115(4), 1039–1051.
18. Sumit M.; et al. Dissecting N‑Glycosylation Dynamics in Chinese Hamster Ovary Cells Fed‑Batch Cultures Using Time‑Course Omics Analyses. iScience 2019, 19, 782–795.